This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Research » Trials

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

CHMP Recommends Approval of Novo Nordisk's Victoza(R) (Liraglutide) for Type 2 Diabetes

Posted: Wednesday, May 20, 2009

Novo Nordisk announces that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMEA) adopted a positive opinion, recommending marketing authorization, for Victoza® for the treatment of Type 2 diabetes.

Basal-Bolus Injection vs. Basal-Bolus Insulin Pump in Type 1s

Posted: Wednesday, May 20, 2009

To compare injects by syringe and using an insulin pump a randomized open parallel multicenter study was done.

Australian Docs Discover a Type 1 Diabetes Breakthrough

Posted: Tuesday, May 12, 2009

Australian doctors believe they have found the key to eradicating Type 1 diabetes, the kind that obliges sufferers to regulate their blood glucose levels every day of their lives.

Lacosamide Safely Reduces Pain of Diabetic Neuropathy

Posted: Tuesday, May 12, 2009

The antiepileptic drug lacosamide is effective in reducing painful diabetic neuropathy without serious side effects, according to results from two phase 3 trials, one in the United States and one in the European Union, researchers reported at the American Academy of Neurology (AAN) 61st Annual Meeting.

Antibiotic Use in Childhood Not Linked to Type 1 Diabetes

Posted: Tuesday, May 12, 2009

Contrary to what several other studies have shown, the results of a nationwide study of Danish children suggest that antibiotic use does not affect the development of Type 1 diabetes.

Once a Year Byetta in the Diabetes Pipeline

Posted: Wednesday, May 06, 2009

With Lilly/Amylin's submission of their once a week Byetta, another company, Intarcia Therapeutics, Inc., announces completion of enrollment of ITCA 650 phase 1b study for the treatment of Type 2 diabetes with their once a year dosing of Byetta.

Intranasal Insulin Improves Diabetic Neuropathy

Posted: Wednesday, April 29, 2009

Intranasal insulin slows the progression of diabetic peripheral neuropathy. Peak blood concentrations of insulin were nearly 1000-fold lower after intranasal delivery than after subcutaneous delivery.

Transplants Help Type 1 Diabetics Stop Insulin Injections

Posted: Wednesday, April 29, 2009

People with Type 1 diabetes who received stem cell transplants from their own cells were able to go as long as four years without needing insulin treatments, U.S. researchers reported.

Liraglutide Has Low CVD Risk but May Be Blocked for Approval

Posted: Wednesday, April 15, 2009

Tumor data may block approval for diabetes drug liraglutide. An FDA advisory panel declined to recommend approval for the investigational diabetes drug liraglutide (Victoza), in light of animal studies linking the injection to thyroid cancer.

The Next DPP-4 Inhibitor Onglyza™ Passes CVD Review: Coming Soon

Posted: Wednesday, April 15, 2009

An FDA panel voted 10-2 that the investigational diabetes drug saxagliptin (Onglyza) does not put Type 2 diabetes patients at an increased risk for cardiovascular events, but wants drugmaker Bristol-Myers Squibb to conduct long-term postmarketing studies to test the drug in older and sicker patients.